INSTINCT BIO TECHNICAL COMPANY HOLDINGS INC. (Nasdaq: BIOT) has been named the authorized introduction and business development representative for IN01, a clinical-stage cancer immunotherapy, in Japan and the People's Republic of China. The non-exclusive appointment by CelSiege Biosciences Inc., a biotechnology company headquartered in Marseille, France, was formalized through a Letter of Authorisation signed on September 18, 2026. The move marks a significant expansion of BIOT's business development activities into the clinical-stage oncology space, leveraging its expertise in healthcare and biotechnology across Asian markets.
Under the agreement, BIOT may introduce the IN01 Program to prospective strategic partners, investors, pharmaceutical and biotechnology companies, medical institutions, research organizations, and investment funds in both countries. BIOT is also authorized to facilitate preliminary discussions on potential investment, licensing, co-development, clinical development, manufacturing, and commercialization. Any definitive transaction remains subject to separate negotiations, due diligence, and definitive agreements.
The appointment holds strategic importance due to the substantial unmet medical need in oncology, particularly in Japan and China. According to the International Agency for Research on Cancer, lung cancer was the world's most frequently diagnosed cancer in 2022, with approximately 2.5 million new cases and 1.8 million deaths. Non-small cell lung cancer (NSCLC) accounts for approximately 80% to 85% of lung cancer cases, according to the American Cancer Society. Fortune Business Insights estimates the global NSCLC therapeutics market at approximately $38.49 billion in 2025. While this third-party estimate relates to a broad therapeutic category and should not be read as an estimate of the addressable market or commercial potential of IN01, it underscores the scale of the opportunity.
IN01 is an active immunotherapy, or therapeutic cancer vaccine, targeting epidermal growth factor (EGF). It is designed to stimulate the patient's immune system to produce antibodies against circulating EGF, a growth factor involved in the proliferation of certain cancer cells. Development materials identify squamous non-small cell lung cancer (sqNSCLC) as the lead indication, with potential expansion into colorectal, head-and-neck, and other cancers. IN01 is a clinical-stage asset and has not received marketing approval.
"We believe IN01 is a promising clinical-stage program in the field of active cancer immunotherapy, and we are fully committed to helping build a path for this science to reach the patients who need it," said Tomoki Nagano, Chief Executive Officer of BIOT. "Japan and China have the world's largest lung cancer patient populations alongside world-class clinical research capabilities, placing them at the center of unmet medical needs in oncology. We share with CelSiege a mission to bring this technology to patients. As CelSiege's authorized representative in these two markets, BIOT will work with a strong sense of ownership to identify partners and pursue collaborations that can advance the development and commercialization of IN01. Our enduring aspiration is to bring more smiles to patients and their families."
The collaboration aligns with BIOT's broader strategy to build an integrated platform connecting innovative healthcare technologies with growth opportunities across Asia. CelSiege Biosciences focuses on the research and development of active immunotherapies, with a proprietary B-cell-mediated platform designed to stimulate polyclonal antibody responses against disease-associated ligands. For more information, visit CelSiege Biosciences. BIOT's corporate website is available at https://instinct-biot.com/.
The announcement was originally distributed via NEWMEDIAWIRE.
